Skip to content
Parakho

AstraZeneca Pharma India Ltd

NSE ASTRAZENBSE 506820

Q1 FY27, unaudited

Revenue
₹682.79 Cr
Profit after tax
₹37.93 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations682.79+29.73%2,275.58
Other income9.23−17.88%28.49
Total income692.02+28.74%2,304.07
Employee benefit expense79.16+22.82%264.38
Finance costs1.95+170.83%4.49
Depreciation & amortisation5.23−68.44%28.58
Total expenses641.03+38.60%2,046.62
Profit before tax50.75−32.06%252.20
Tax expense12.82−32.06%64.68
Profit after tax37.93−32.06%187.52
Total comprehensive income37.63−33.33%183.08
Earnings per share
Earnings per share, basic₹15.17₹75.01
Earnings per share, diluted₹0.00₹0.00

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

AstraZeneca Pharma India Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 43 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.